Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K7 | O14733 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 10/20 | 0.49 |
| ▸ | TNNI3K | Q59H18 | 10/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.47 |
| ▸ | BRAF | P15056 | 7/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5319197 | 0.86 | KMO (0.52) | MAP2K7KDRTNNI3KMAP4K4MAPK14 | |
| SCHEMBL14447587 | 0.86 | MAP2K7 (0.54) | MAP2K7KDRTNNI3KMAPK14BRAF | |
| SCHEMBL5319488 | 0.85 | MAP4K4 (0.46) | MAP2K7KDRTNNI3KMAP4K4MAPK14 | |
| SCHEMBL5446984 | 0.85 | MAP4K4 (0.48) | MAP2K7KDRTNNI3KMAP4K4MAPK14 | |
| SCHEMBL22541668 | 0.85 | KDR (0.60) | MAP2K7KDRTNNI3KMAP4K4MAPK14 | |
| SCHEMBL5319339 | 0.85 | KDR (0.47) | MAP2K7KDRTNNI3KMAP4K4MAPK14 | |
| SCHEMBL14447591 | 0.85 | MAP4K4 (0.46) | MAP2K7KDRTNNI3KMAP4K4MAPK14 | |
| SCHEMBL16895205 | 0.85 | MAP4K4 (0.45) | KDRMAP4K4CYP17A1MAPKAPK2CDK1 | |
| SCHEMBL14447567 | 0.83 | MAP4K4 (0.47) | MAP2K7KDRTNNI3KMAP4K4MAPK14 | |
| SCHEMBL5317810 | 0.83 | KDR (0.45) | MAP2K7KDRTNNI3KMAP4K4MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | BRAF, ARAF, RAF1 | MAP2K7 141/4885KDR 555/4885TNNI3K 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.